DV
Dividend Vision

RCKT Stock — Rocket Pharmaceuticals Inc

Rocket Pharmaceuticals Inc (RCKT)

Updated October 16, 2026.

RCKT is a Stock. Total return is -90.9% over the past 11.7 years, 431.7 points behind SPY at 340.8%.

Rocket Pharmaceuticals is a late-stage biotechnology company developing genetic therapies for rare and devastating diseases, including in vivo adeno-associated viral programs for heart conditions and ex vivo lentiviral programs for blood and immune disorders. The company does not currently distribute income to shareholders. This company is typical of clinical-stage biotech firms and appeals to investors focused on long-term growth potential rather than current income.

RCKT dividend yield and income

Price as of 2026-10-16.

The payment date is 01/05/2018.

RCKT performance versus SPY

Price and return data through 2026-10-16.

Total return is -90.9% over the past 11.7 years, 431.7 points behind SPY at 340.8%. Over the past year its total return — price change plus distributions reinvested — is -45.5%. Its deepest 1-year drawdown was 58.9%.

WindowTotal returnCAGR
1M-37.4%—
3M-36.1%—
6M-44.1%—
YTD-37.9%—
1Y-45.5%—
2Y CAGR—-65.30%
3Y CAGR—-50.00%
5Y CAGR—-39.90%
10Y CAGR—-23.30%
Since inception (11.7 years)-90.9%-18.60%

RCKT key facts

Asset type
Stock
Asset class
Equity
Inception date
02/18/2015
Distribution frequency
None
Last close
$2.18 (as of 2026-10-16)
Market cap
$239,308,621
Average volume
1966675.0
Payment date
01/05/2018
Beta
0.497
Payout ratio
0.0%
EPS
$-0.17

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

RCKT risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 58.9%.

Who may consider RCKT — and who may not

It is a weaker fit for investors who need monthly cash flow (RCKT does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on RCKT

Tagged: Healthcare.

Frequently asked questions

Does RCKT pay monthly?

No. RCKT does not currently distribute.

When does RCKT pay a dividend?

RCKT does not currently distribute. The payment date is 01/05/2018.

How has RCKT performed?

Total return is -90.9% over the past 11.7 years, 431.7 points behind SPY at 340.8%. Over the past year its total return — price change plus distributions reinvested — is -45.5%. Its deepest 1-year drawdown was 58.9%.

DividendVision analysis is generated from public SEC filing data and may not capture every change. Review the original filing for complete information.